Related Experiment Video

Updated: Jul 15, 2026

Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology
10:46

Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology

Published on: May 26, 2015

Catheter ablation of atrial fibrillation in patients with hyperthyroidism

Chang Sheng Ma1, Xu Liu, Fu Li Hu

  • 1Ward 2nd, Department of Cardiology, Beijing Anzhen Hospital, Capital University of Medical Sciences, Chaoyang District, Beijing, People's Republic of China. chshma@vip.sina.com

Journal of Interventional Cardiac Electrophysiology : an International Journal of Arrhythmias and Pacing
|April 21, 2007
PubMed

Insights

Catheter ablation effectively treated atrial fibrillation in hyperthyroid patients. Circumferential pulmonary vein ablation (CPVA) offered a viable option for those unresponsive to medication.

Area of Science:

  • Cardiology
  • Electrophysiology
  • Endocrinology

Background:

  • Hyperthyroidism frequently coexists with atrial fibrillation (AF), posing treatment challenges.
  • Drug-refractory AF in euthyroid hyperthyroid patients requires alternative therapeutic strategies.

Purpose of the Study:

  • To assess the clinical effectiveness of catheter ablation for atrial fibrillation in patients with a history of hyperthyroidism.

Main Methods:

  • 16 patients with hyperthyroidism-related AF, refractory to antiarrhythmia drugs, underwent circumferential pulmonary vein ablation (CPVA).
  • A 3-D mapping system guided the procedure, aiming for pulmonary vein isolation.

Main Results:

  • CPVA was performed safely in all patients, achieving pulmonary vein isolation.
  • After a mean follow-up of 15.8 months, 56% of patients were free from atrial tachyarrhythmia without antiarrhythmia drugs.

Conclusions:

  • Circumferential pulmonary vein ablation is a potential therapeutic option for managing atrial fibrillation in hyperthyroid patients.
  • This catheter ablation technique offers an alternative for patients with drug-refractory AF linked to hyperthyroidism.
Abstract

More Related Videos

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

Robotic Ablation of Atrial Fibrillation11:21

Robotic Ablation of Atrial Fibrillation

Published on: May 29, 2015

Related Concept Videos

ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias01:25

ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias

Arrhythmia is a condition characterized by an irregular heart rhythm, with ECG changes that differ based on its origin and nature. The types of arrhythmias discussed below include atrial, junctional, and ventricular arrhythmias.Atrial ArrhythmiasPremature Atrial Complexes (PACs): PACs are early atrial beats caused by stress, caffeine, alcohol, electrolyte imbalances, hypoxia, hyperthyroidism, or certain medications (e.g., bronchodilators and decongestants). The ECG shows early P waves with an...
Disturbances in Heart Rhythm01:29

Disturbances in Heart Rhythm

Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...
Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
Hyperthyroidism II: Pathophysiology01:27

Hyperthyroidism II: Pathophysiology

Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH receptors...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
Hyperthyroidism I: Introduction01:25

Hyperthyroidism I: Introduction

Hyperthyroidism is a type of thyrotoxicosis characterized by the thyroid gland's overproduction of the thyroid hormones triiodothyronine (T3) and thyroxine (T4). This hormone excess increases the basal metabolic rate and enhances sensitivity to catecholamines.DiagnosisDiagnosis is based on clinical features and biochemical testing. It typically shows suppressed thyroid-stimulating hormone (TSH) levels below 0.4 mIU/L, with elevated free T3 and/or T4. Additional tests, including thyroid...